Background/Purpose. Several studies reported chemosensitive dysfunction in the olfactory and gustatory domains following coronavirus disease 2019 (COVID-19). However, the long-term convalescence period of these sensory functions and associated factors remains unknown. Hence, this study explored the correlation between post-COVID-19 conditions, chemosensitive function, blood group, and oral health-related quality of life. Materials and Methods. A cross-sectional information on demographics, symptomatic disease status, ABO blood group, and oral health-related quality of life (OHRQoL) was collected among 100 patients who were earlier tested positive for COVID-19 reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and were now reporting to the College of Dentistry for routine treatment after recovery. Objective evaluation of olfactory and gustatory disturbances was elicited using the Connecticut Chemosensory Clinical Research Center (CCCRC) test and gustatory function testing. Furthermore, OHRQoL was assessed using Oral Health Impact Profile (OHIP-14). Results. More than half of the patients (62%) had some form of olfactory dysfunction/alteration, and 42% had poor CCCRC scores. About 14% reported ageusia, while 68% reported some form of taste alterations, and 55% reported poor OHRQoL. A statistically significant difference was reported between different ABO blood groups and subjective loss of smell ($p < 0.05$). The subjective loss of taste, CCCRC score, and dysgeusia were found to be independent of OHIP-14 ($p > 0.05$), but the taste intensity score was dependent on OHIP 14 ($p < 0.05$). Moreover, a majority (70.8% and 70.0%) with poor OHIP-14 scores had taste intensity scores of 3 and 4, respectively, while those with moderate (68.4% and 48.6%) OHIP-14 had scored 1 and 2, respectively. Conclusion. Olfactory and gustatory disturbances were found to be a long-term feature in post-COVID-19 patients. The blood group is a predisposing factor for persistent smell alterations in post-COVID-19 patients.
of the disease is crucial for timely identification [9]. Furthermore, numerous studies concluded that anosmia without nasal obstruction and dysgeusia is a pathognomonic sign of COVID-19 infection [10, 11]. Earlier studies have established the link between postviral olfactory symptoms with human rhinovirus, parainfluenza, and Epstein–Barr virus.

A recent meta-analysis of 155 studies across the globe revealed variable prevalence ranging from olfactory (0%–98%) and gustatory dysfunction (0–89%) [12]. Though some patients have reported isolated olfactory or taste disturbance, most complained of combined olfactory and taste alterations. The period between exposure and COVID-19 appearance of symptoms takes 5–6 days with the variation of 1 day to 2 weeks. Most of these patients reported complete recovery; however, evidence suggested prolonged, persistent dysfunction for an extended period, qualifying olfactory and gustatory disturbances as a post-COVID-19 condition. Post-COVID-19 syndrome has been used to refer to any health disorder or disorder that persists for more than a month in people who suffered from mild COVID-19 or were even asymptomatic [13]. There is no substantial unanimity on post-COVID-19 symptoms, and its diagnostic criteria have not been sufficiently established. The varied manifestations of these post-COVID-19 conditions between individuals and the convalescence period it may last are still questionable. The disability associated with the symptoms of the post-COVID-19 syndrome is one of its main characteristics, so the impact it can have on the care and rehabilitation units is considerable. Most studies have focused on analyzing the prevalence of symptoms of a post-COVID-19 syndrome rather than on objective organ involvement. The absence of a standard and accepted definition limits the comparison of findings between the various epidemiological studies [14, 15]. Studies showed that olfactory and gustatory impairments are long-lasting sequelae of COVID-19. Even after 30 to 50 days, patients still suffered from objectifiable smell and taste disorders. The absence of research in this perspective ignited up this piece of an audit [3, 6, 12, 15, 16].

Association of ABO blood group typing with infectious diseases is not just a causal relationship. Various studies often show that blood groups have a direct impact on disease courses and prognosis. There is a well-established correlation between blood groups and numerous viral infections like the Norwalk virus and Hepatitis B [17–19]. A recent meta-analysis of this human respiratory disease with ABO grouping revealed mixed results among various countries [17]. Nonetheless, none of the studies so far assessed the relationship between the severities of olfactory and gustatory disturbances with blood group correlation in COVID-19. Such a relationship could be of significant prognostic value and treatment planning. Furthermore, none of the studies assessed the relationship between olfactory and gustatory disturbance severity with blood group correlation in COVID-19 circumstances, which, if found, could aid in prognosis and treatment planning.

The COVID-19 pandemic has impacted the health-related quality of life of all sectors of the population [20, 21]. To our knowledge, none of the studies explored the long-term effects of olfactory and gustatory impairment in post-COVID-19 patients and its effect on OHRQoL in these subjects. The null hypothesis of this study was that there is no difference in the chemosensitive function in patients with and without post-COVID-19 and there was no association between these dysfunctions and their ABO blood group. Thus, the present study aimed to identify chronic chemosensitive dysfunction in post-COVID-19 patients by objective assessment methods and determine if any association between these dysfunctions and their ABO blood group existed. This study also explored the impact of olfactory and gustatory impairment on OHRQoL among these patients.

2. Materials and Methods

This cross-sectional study was conducted among 116 participants who reported to the Outpatient Department of Oral Diagnosis, College of Dentistry, King Khalid University, Saudi Arabia, using convenience sampling from March to September 2021. Ethical approval was obtained from the Institutional Review Board of King Khalid University (IRB/KKUCOD/ETH/2020-21/050). This study adhered to the code of ethics in the Declaration of Helsinki protocol (version 17C, 2004). Complete information about the study was given to the patients in their language, and informed consent was sought before the commencement of the study.

2.1. Participants. The inclusion criteria of this study were patients older than 18 years who had COVID-19 infection and became negative in the COVID-19 reverse transcription-quantitative polymerase chain reaction (RT-qPCR) test. These patients were recruited for the study. Patients who had a history of olfactory and taste function alterations before COVID-19 and a history of any systemic disease and smokers were excluded from the study in order to eliminate potential sources of bias.

2.2. Variables. The primary investigator (RA) collected demographic data, COVID-19 RT-qPCR test details, and ABO blood group from the patient medical records. Objective assessment of olfaction and gustatory functions and OHRQoL were conducted by the co-investigators of the study (RM, MA, and MH). The olfactory assessment was done using the CCCRC test and odour identification test [22].

2.3. Sources of Data and Details of Methods of Assessment

2.3.1. Butanol Threshold Test. In each case, participants were presented with two identical glass bottles simultaneously—one containing water and the other containing a dilute concentration of butanol. They were instructed to occlude one nostril and place the tip of the first bottle immediately beneath the other nostril. The second bottle was then sampled similarly, and the participants had to choose which of the bottles contained something other than water. If the choice was incorrect, the next stronger butanol concentration was presented along with a bottle containing
only water. Once the subject correctly identified the same butanol concentration five times in a row, the score was recorded for that nostril. The other nostril was then tested separately, and the scores for both nostrils were averaged to arrive at the final score. The most potent butanol concentration (bottle 0) was 4% butanol in deionized water. Each subsequent dilution (bottles 1–9) was a 1:3 dilution with deionized water. Possible scores ranged from 0 to 9, but all scores seven and higher were scored according to the Connecticut Chemosensory Clinical Research Center (CCCRC) test.

2.3.2. Odour Identification Test. Common household odors were kept inside opaque jars. Participants chose from a printed list containing the correct items and an equal number of distractor items. Possible scores ranged from 0 to 7 for items that were accurately identified. Scores for both nostrils were averaged to arrive at the final score. Scores for the butanol threshold test and identification were subsequently averaged to arrive at a composite score for olfactory function [22].

2.3.3. Gustatory Function. Gustatory function in the participants was analyzed using a standardized and validated test that investigated the ability to perceive four primary tastes. Gustatory testing covered the four essential gustatory qualities sweet, salty, sour, and bitter. Four solutions for each primary taste were prepared in water using table salt, refined sugar, lemon juice, and unsweetened decaffeinated coffee. According to the correct answers, four categories of taste intensity scores were established: normal (score 4), mild hypogeusia (score 3), moderate hypogeusia (score 2), severe hypogeusia (score 1), and ageusia (score 0) [16]. Subjective loss of smell, loss of taste, and dysgeusia were also recorded for each patient.

2.3.4. Oral Health-Related Quality of Life (OHRQoL). Oral health-related quality of life was assessed using a standardized OHIP-14 questionnaire. It is a self-reported questionnaire focusing on seven dimensions (functional limitation, pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap) of oral health. Participants were asked to respond on a five-point Likert scale: never coded (score 0), hardly ever (score 1), occasionally (score 2), fairly often (score 3), and very often (score 4). The total score of the OHIP-14 was calculated by adding the scores of the responses for the 14 items. The values of the OHIP-14 score ranged from 0 to 56, with higher scores indicating lower OHRQoL [23].

2.3.5. Statistical Analysis. The collected data were subjected to statistical analysis using appropriate statistical tools. All data were represented as frequency and percentage (for categorical variables). The chi-square test has been used for finding an association between regular exercise and various study variables. If expected frequencies are less than five, either continuity correction for chi-square or Fisher’s exact test has been employed. A calculated p value less than 0.05 is considered statistically significant. All the analyses were carried out with the help of the commercially available statistical package SPSS v.23 for WINDOWS.

3. Results

One hundred sixteen patients were found potentially eligible and examined for the study. One hundred were confirmed eligible and included in the study as they consented to participate and completed the evaluation (twelve participants did not complete the olfactory and gustatory tests, while four did not complete the OHIP-14 questionnaire; hence, their data were not considered for the analysis). The frequency and percentage distribution of patients based on demographic characteristics are presented in Table 1. There were 48% females and 52% males. The majority of the study participants (65%) were below 30 years of age, and more than half (64%) were married. The study participant’s educational qualifications included a university degree (61%), high school (28%), secondary school (8%), and primary school (3%). Most of the participants (46%) had O blood group followed by A group (32%), B group (14%), and AB blood group (8%).

Table 2 lists patients’ frequency and percentage distribution based on duration after COVID-19, subjective loss of smell and taste, CCCRC score, taste intensity score, dysgeusia, and OHIP-14 score. Most of the study patients (54%) suffered from COVID-19 seven months ago or earlier. About 31% had the disease 4–6 months before the current study, while a small proportion (15%) reported being tested COVID-19 positive within the last three months. About 38% of subjects did not have any olfactory disturbances at the study time, while 8% presented with persistent anosmia at the time of the study. More than half of the patients had...
either mild, moderate, or severe anosmia when tested. Furthermore, 42% had poor CCCRC scores when screened objectively for olfactory function. When analyzing the neural impairment in the gustatory domain, 14% reported ageusia. More than half of the study population had mild, moderate, or severe hypogeusia, similar to the olfactory disturbance. Taste intensity score revealed only 20% had a normal taste, while the remaining 80% had any one of the forms of taste alterations and dysgeusia in 12% of the study population. More than half of the study participants (55%) reported poor OHRQoL, and notably, none of the participants had an excellent OHRQoL score. A statistically significant difference was reported between different ABO blood groups and subjective loss of smell ($p < 0.05$). However, other variables like subjective loss of taste, CCCRC score, and taste intensity score did not show any association with the ABO blood group (Table 3). Subjective loss of taste showed association with the ABO blood group when grouped as positive and negative (Table 4). No statistically significant association was found between most of the evaluated variables (subjective loss of taste, CCCRC score, and dysgeusia) and OHIP-14 score ($p > 0.05$), that is, subjective loss of taste, CCCRC score, and dysgeusia are independent of OHIP-14. However, there was a statistically significant association between taste intensity scores and OHIP-14 scores ($p < 0.05$). Hence, the taste intensity score is dependent on OHIP 14. The majority of the patients (70.8% and 70.0%) with poor OHIP-14 had taste intensity scores of 3 and 4, while those with moderate (68.4% and 48.6%) OHIP-14 had scored 1 and 2 (Table 5).

4. Discussion
To the best of our knowledge, this is the first study in Saudi Arabia that reports the presence of chronic chemosensitive dysfunction in post-COVID-19 patients using objective assessment methods and, at the same time, explores the association between these dysfunctions and their ABO blood group and OHRQoL. It was found that most of the participants had some form of olfactory and gustatory impairment following COVID-19 infection and experienced poor OHRQoL. While many aspects of chemosensitive functions were found to be independent of OHRQoL, the taste intensity score was found to be dependent on it. Various authors have reported the gustatory and olfactory disturbance to have a significant predictive value in the acute phase of COVID-19 [24, 25]. The possible pathophysiology of postinfection chemosensitive disorders could be attributed to either damage to the olfactory/epithelium or its central processing pathways [1, 26].

### Table 2: Frequency and percentage distribution of patients based on duration after COVID-19, subjective loss of smell and taste, CCCRC score, taste intensity score, dysgeusia, OHIP-14 score.

| Variable | Class | Frequency | Percentage |
|----------|-------|-----------|------------|
| Duration after recovering from COVID-19 | Less than or equal to 3 months | 15 | 15.0 |
| | 4–6 months | 31 | 31.0 |
| | Greater than or equal to 7 months | 54 | 54.0 |
| | Total | 100 | 100.0 |
| Subjective loss of smell | Anosmia | 8 | 8.0 |
| | Severe hyposmia | 14 | 14.0 |
| | Moderate hyposmia | 28 | 28.0 |
| | Mild hyposmia | 12 | 12.0 |
| | Normal | 38 | 38.0 |
| | Total | 100 | 100.0 |
| Subjective loss of taste | Ageusia | 14 | 14.0 |
| | Severe hypogeusia | 15 | 15.0 |
| | Moderate hypogeusia | 27 | 27.0 |
| | Mild hypogeusia | 12 | 12.0 |
| | Normal | 32 | 32.0 |
| | Total | 100 | 100.0 |
| CCCRC score | Good | 58 | 58.0 |
| | Poor | 42 | 42.0 |
| | Total | 100 | 100.0 |
| Taste intensity score | 1 | 19 | 19.0 |
| | 2 | 37 | 37.0 |
| | 3 | 24 | 24.0 |
| | 4 | 20 | 20.0 |
| | Total | 100 | 100.0 |
| Presence of dysgeusia | No | 88 | 88.0 |
| | Yes | 12 | 12.0 |
| | Total | 100 | 100.0 |
| OHIP-14 score | Poor | 56 | 56.0 |
| | Moderate | 44 | 44.0 |
| | Total | 100 | 100.0 |
Pathogenic susceptibility of SARS-CoV-2 in olfactory alterations, gustatory domain, and ABO blood groups varies remarkably among different populations [14, 19, 27, 28]. A recent study of 47,910 COVID-19 susceptible individuals showed varied recovery rates [14]. The exact time these symptoms resolve is unknown, necessitating in-depth studies to analyze post-COVID-19 sequelae. Chemosensitive dysfunction, especially olfactory and gustatory, has a more significant effect on domestic incidents and eating disorders, compromising the quality of life significantly [20, 29, 30]. Hence, studies on the epidemiology and post-COVID-19 conditions are the need of the hour to develop evidence-based principles directed to sustain the quality of life among these patients.

In the present study, we had only a handful of studies included in the discussion as very few works evaluated the post-COVID-19 olfactory and gustatory disturbances. Moreover, none of the studies evaluated OHRQoL in post-COVID-19 conditions. In this study, post-COVID-19 conditions of taste and smell disturbances among patients who had recovered from the infection were assessed on an average of 60 days to 210 days after disease onset. Olfactory disorders, either partial or total, were reported in 73% of the population with 8% anosmia. This overall olfactory compromise found in this work did not corroborate with the short-term recovery reported by a multicentric study done in India (85%), France (64%), and Europe (44%), respectively [1, 31, 32].

In terms of hyposmia, the proportion reported in this work is much higher than that reported in similar studies. About 32% of hyposmia conditions are declared in Chinese patients when assessed objectively three months after hospitalization [33]. An Israeli study assessed post-COVID-19 hyposmia among 112 patients between 6 weeks to 6 months after symptoms proclaimed 15% smell change [34]. Further, in a survey among 488 hospitalized COVID-19 positive patients, Chopra and his colleagues found about 13.1% reported the loss of smell 60 days after hospital discharge following the infection [35]. Similarly, another study among the Austrian population found that 19% had anosmia or hyposmia 100 days after symptom onset [36]. A Norwegian study found 12% smell dysfunction with a mean age of 50 years in 41 to 193 days after disease onset [37]. Another prospective geographical cohort study done by Peterson et al. among patients with a mean age of 40 years, 24% reported loss of smell 125 days after disease onset [38]. A recent analysis by Gerkin and his colleagues reported only 40.9% of patients fully recovered after 40 days following the disease onset [39]. Iannuzzi et al. declared that their work could not conclude the full-term recovery of smell two months after rehabilitation [40]. The relatively high percentage of hyposmia may be attributed to the objective nature or validated olfactory tests we used.

Nonetheless, most of the previous literature relied on questionnaires or interviews, which were not quantified in sensory functions. Hence, the proportion reported could not be adequately classified as either partial or complete loss. Awareness of the association between taste alteration and post-COVID-19 is essential for patient management and betterment of public health [13]. Our study found more than half of the subjects had taste alterations, 54% hypogeusia, and 18% ageusia. These findings were similar to the studies

| Chemosensitive dysfunction | ABO blood groups | Chi-square | df | p value |
|---------------------------|-----------------|------------|----|--------|
| **Subjective loss of smell** |                 |            |    |        |
| Anosmia                   | A: 2 (25.0%)    | 1 (12.5%)  | B: 2 (25.0%) | 3 (37.5%) | 24.362 | 12 | 0.006** |
| Severe hyposmia           | A: 3 (21.4%)    | 1 (7.1%)   | B: 2 (14.3%) | 8 (57.1%) |         |    |        |
| Moderate hyposmia         | A: 13 (46.4%)   | 4 (14.3%)  | B: 3 (10.7%) | 8 (28.6%) |         |    |        |
| Mild hyposmia             | A: 9 (75.0%)    | 0 (0.0%)   | B: 1 (8.3%)  | 2 (16.7%) |         |    |        |
| Normal                    | A: 5 (13.2%)    | 2 (5.3%)   | B: 6 (15.8%) | 25 (65.8%)|         |    |        |
| **Subjective loss of taste** |               |            |    |        |
| Ageusia                   | A: 3 (21.4%)    | 1 (7.1%)   | B: 3 (21.4%) | 7 (50.0%) |         |    |        |
| Severe hypogeusia         | A: 5 (33.3%)    | 2 (13.3%)  | B: 2 (13.3%) | 6 (40.0%) |         |    |        |
| Moderate hypogeusia       | A: 12 (44.4%)   | 3 (11.1%)  | B: 3 (11.1%) | 9 (33.3%) |         |    |        |
| Mild hypogeusia           | A: 7 (58.3%)    | 0 (0.0%)   | B: 1 (8.3%)  | 4 (33.3%) |         |    |        |
| Normal                    | A: 5 (15.6%)    | 2 (6.2%)   | B: 5 (15.6%) | 20 (62.5%)|         |    |        |
| **CCCRC score**           |                 |            |    |        |
| Good                      | A: 18 (31.0%)   | 3 (5.2%)   | B: 9 (15.5%) | 28 (48.3%)| 1.806   | 3  | 0.619 NS |
| Poor                      | A: 14 (33.3%)   | 5 (11.9%)  | B: 5 (11.9%) | 18 (42.9%)|         |    |        |
| **Dysgeusia**             |                 |            |    |        |
| No                        | A: 29 (33.0%)   | 7 (8.0%)   | B: 13 (14.8%) | 39 (44.3%)| 0.952   | 3  | 0.839 NS |
| Yes                       | A: 3 (25.0%)    | 1 (8.3%)   | B: 1 (8.3%)  | 7 (58.3%) |         |    |        |
| **Taste intensity score** |                 |            |    |        |
| 1                         | A: 6 (31.6%)    | 1 (5.3%)   | B: 3 (15.8%) | 9 (47.4%) |         |    |        |
| 2                         | A: 6 (16.2%)    | 3 (8.1%)   | B: 4 (10.8%) | 24 (64.9%)| 13.888  | 9  | 0.096 NS |
| 3                         | A: 9 (37.5%)    | 2 (8.3%)   | B: 4 (16.7%) | 9 (37.5%) |         |    |        |
| 4                         | A: 11 (55.0%)   | 2 (10.0%)  | B: 3 (15.0%) | 4 (20.0%) |         |    |        |

NS: not significant (p>0.05) *: significant (p<0.05).
Table 4: Chi-square test of association between positive and negative blood groups and chronic chemosensitive dysfunction in post-COVID-19 patients (fisher's exact test).

| Chemosensitive dysfunction | ABO blood groups | Chi-square | df | p value |
|---------------------------|------------------|------------|----|---------|
|                           | Positive | Negative |                |        |
| Subjective loss of smell  |          |          |                |        |
| Anosmia                   | 8 (100.0%) | 0 (0.0%) | 6.058         | 4      | 0.127 NS |
| Severe hyposmia           | 12 (85.7%) | 2 (14.3%) |              |        |
| Moderate hyposmia         | 28 (100.0%) | 0 (0.0%) |              |        |
| Mild hyposmia             | 10 (83.3%) | 2 (16.7%) |              |        |
| Normal                    | 32 (86.5%) | 5 (13.5%) |              |        |
| Subjective loss of taste  |          |          |                |        |
| Ageusia                   | 11 (84.6%) | 2 (15.4%) | 7.835         | 4      | 0.049 * |
| Severe hypogeusia         | 13 (86.7%) | 2 (13.3%) |              |        |
| Moderate hypogeusia       | 27 (100.0%) | 0 (0.0%) |              |        |
| Mild hypogeusia           | 9 (75.0%) | 3 (25.0%) |              |        |
| Normal                    | 30 (93.8%) | 2 (6.2%) |              |        |
| CCCRC score               |          |          |                |        |
| Good                      | 53 (93.0%) | 4 (7.0%) | 0.233         | 1      | 0.630 NS |
| Poor                      | 37 (88.1%) | 5 (11.9%) |              |        |
| Taste intensity score     |          |          |                |        |
| 1                         | 18 (94.7%) | 1 (5.3%) |              |        |
| 2                         | 34 (94.4%) | 2 (5.6%) | 3.226         | 3      | 0.385 NS |
| 3                         | 22 (91.7%) | 2 (8.3%) |              |        |
| 4                         | 16 (80.0%) | 4 (20.0%) |              |        |
| Dysgeusia                 |          |          |                |        |
| No                        | 79 (90.8%) | 8 (9.2%) | 0.000         | 1      | 1.000 NS |
| Yes                       | 11 (91.7%) | 1 (8.3%) |              |        |

NS: not significant (p > 0.05) *: significant (p < 0.05).

Table 5: Chi-square test of association between OHIP14 (oral health index profile) and chronic chemosensitive dysfunction in post-COVID-19 patients (fisher's exact test).

| Chemosensitive dysfunction | OHIP14 | Chi-square | df | p value |
|---------------------------|--------|------------|----|---------|
|                           | Poor   | Moderate   |    |         |
| Subjective loss of smell  |        |            |    |         |
| Anosmia                   | 5 (62.5%) | 3 (37.5%) | 4.168 | 4 | 0.393 NS |
| Severe hyposmia           | 6 (42.9%) | 8 (57.1%) |              |        |
| Moderate hyposmia         | 13 (46.4%) | 15 (53.6%) |              |        |
| Mild hyposmia             | 9 (75.0%) | 3 (25.0%) |              |        |
| Normal                    | 23 (60.5%) | 15 (39.5%) |              |        |
| Subjective loss of taste  |        |            |    |         |
| Ageusia                   | 9 (64.3%) | 6 (35.7%) | 6.624 | 4 | 0.157 NS |
| Severe hypogeusia         | 8 (53.3%) | 7 (46.7%) |              |        |
| Moderate hypogeusia       | 11 (40.7%) | 16 (59.3%) |              |        |
| Mild hypogeusia           | 10 (83.3%) | 2 (16.7%) |              |        |
| Normal                    | 18 (56.2%) | 14 (43.8%) |              |        |
| CCCRC score               |        |            |    |         |
| Good                      | 32 (55.2%) | 26 (44.8%) | 0.038 | 1 | 0.845 NS |
| Poor                      | 24 (57.1%) | 18 (42.9%) |              |        |
| Taste intensity score     |        |            |    |         |
| 1                         | 6 (31.6%) | 13 (68.4%) | 8.657 | 3 | 0.034 * |
| 2                         | 19 (51.4%) | 18 (48.6%) |              |        |
| 3                         | 17 (70.8%) | 7 (29.2%) |              |        |
| 4                         | 14 (70.0%) | 6 (30.0%) |              |        |
| Dysgeusia                 |        |            |    |         |
| No                        | 48 (54.5%) | 40 (45.5%) | 0.630 | 1 | 0.427 NS |
| Yes                       | 8 (66.7%) | 4 (33.3%) |              |        |

NS: not significant (p > 0.05) *: significant (p < 0.05).
done by Peterson et al. [38] (15%) and Sonnweber et al. [36] (19%) but higher than reported by Stavem et al. [37] (10%), Chopra et al. [35] (13%), and Klein et al. [34] (8%).

In the present study, ABO blood grouping was a predisposing factor for persistent anosmia after COVID-19 infection, and a prevalence of an O blood group was seen. However, Mahmud et al. [41] found a higher prevalence of A blood group among COVID-19 patients and no association of ABO blood groups with the clinical presentation or duration of recovery from COVID-19. Similarly, Badedi et al. [42] did not find any significant association between a specific ABO blood group and mortality risk in COVID-19 positive patients. The overall results of this study lead to the rejection of our null hypothesis.

Persistent impairment of olfactory and gustatory chemosensory senses compromises the quality of life in general and oral health in particular. An association between objective measurement of taste intensity and OHRQoL has been reported in our work. Several research studies that assessed chemosensory disorder used only subjective measurement, influencing the prevalence rates [43]. In this regard, there are suggestions in the literature for dental treatment during the pandemic periods, especially in a vulnerable population to avoid more serious complications [44].

Although this is a first of its kind study that examines the correlation between post-COVID-19, chemosensory function, blood group, and oral health-related quality of life, this study has certain limitations. The relatively small sample size of this study is a limitation of this study. Moreover, only patients who reported dental treatment at the outpatient department were included, thus reducing this study’s generalizability and external validity. Further long-term multicentric studies are being planned to fully understand the extent of residual impact of these chemosensory dysfunctions.

In conclusion, this research demonstrates long-term impairment of taste and smell in COVID-19 positive patients identifying it as a definite post-COVID-19 condition in this population. Within the study’s limitations, the blood group is a predisposing factor for persistent anosmia in post-COVID-19 patients.

**Data Availability**

Data will be made available on request to the corresponding author.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] E. Chary, F. Carsuzzaa, J.-P. Trijolet et al., “Prevalence and recovery from olfactory and gustatory dysfunctions in COVID-19 infection: a prospective multicenter study,” *American Journal of Rhinology & Allergy*, vol. 34, no. 5, pp. 686–693, 2020.

[2] E. Mehraeen, F. Behnezad, M. A. Salehi, T. Noori, H. Harandi, and S. SeyedAlinaghi, “Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence,” *European Archives of Oto-Rhino-Laryngology*, vol. 278, no. 2, pp. 307–312, 2021.

[3] A. T. Cruz and S. L. Zeichner, “COVID-19 in children: initial characterization of the pediatric disease,” *Pediatrics*, vol. 145, no. 6, 2020.

[4] A. Gupta, M. V. Madhavan, K. Sehgal et al., “Extrapulmonary manifestations of COVID-19,” *Nature Medicine*, vol. 26, no. 7, pp. 1017–1032, 2020.

[5] X. Jin, J. S. Lian, J. H. Hu et al., “Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms,” *Gut*, vol. 69, no. 6, pp. 1002–1009, 2020.

[6] S. Recalcati, “Cutaneous manifestations in COVID-19: a first perspective,” *Journal of the European Academy of Dermatology and Venereology: JEADV*, vol. 34, no. 5, pp. e212–e213, 2020.

[7] J. P. Rogers, E. Chesney, D. Oliver et al., “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic,” *The Lancet Psychiatry*, vol. 7, no. 7, pp. 611–627, 2020.

[8] B. Schurink, E. Roos, T. Radonic et al., “Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study,” *The Lancet Microbe*, vol. 1, no. 7, pp. e290–e299, 2020.

[9] D. K. C. Wong, H. S. Gendeh, H. K. Thong et al., “A review of smell and taste dysfunction in COVID-19 patients,” *Medical Journal of Malaysia*, vol. 75, no. 5, pp. 574–581, 2020.

[10] L. Mao, H. Jin, M. Wang et al., “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China,” *JAMA Neurology*, vol. 77, no. 6, pp. 683–690, 2020.

[11] S. Pallanti, “Importance of SARS-CoV-2 anosmia: from phenomenology to neurobiology,” *Comprehensive Psychiatry*, vol. 100, Article ID 152184, 2020.

[12] A. Boscutti, G. Delvecchio, A. Pigoni et al., “Olfactory and gustatory dysfunctions in SARS-CoV-2 infection: a systematic review,” *Brain, Behavior, & Immunity—Health*, vol. 15, Article ID 100268, 2021.

[13] F. Salamanna, F. Veronesi, L. Martini, M. P. Landini, and M. Fini, “Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. a systematic review of the current data,” *Frontiers of Medicine*, vol. 8, p. 392, 2021.

[14] F. J. Carod Artal, “Síndrome post-COVID-19: epidemiología, criterios diagnósticos y mecanismos patogénicos implicados,” *Revista de Neurología*, vol. 72, no. 11, pp. 384–396, 2021.

[15] W.-J. Song, C. K. M. Hui, J. H. Hull et al., “Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses,” *The Lancet Respiratory Medicine*, vol. 9, no. 5, pp. 533–544, 2021.

[16] L. A. Vaira, G. Deiana, A. G. Fioc et al., “Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases,” *Head & Neck*, vol. 42, no. 6, pp. 1252–1258, 2020.

[17] W. Jing, G. Zhao, J. Liu, and M. Liu, “ABO blood groups and hepatitis B virus infection: a systematic review and meta-analysis,” *BMJ Open*, vol. 10, no. 1, Article ID e034114, 2020.

[18] J. Li, X. Wang, J. Chen, Y. Cai, A. Deng, and M. Yang, “Association between ABO blood groups and risk of SARS-CoV-2 pneumonia,” *British Journal of Haematology*, vol. 190, no. 1, pp. 24–27, 2020.

[19] J. L. Pendu, A. Breiman, J. Rocher, M. Dion, and N. Ruvoën-Clouet, “ABO blood types and COVID-19: spurious,
anecdotal, or truly important relationships? a reasoned review of available data,” Viruses, vol. 13, no. 2, p. 160, 2021.
[20] M. Desai and J. Oppenheimer, “The importance of considering olfactory dysfunction during the COVID-19 pandemic and in clinical practice,” Journal of Allergy and Clinical Immunology: In Practice, vol. 9, no. 1, pp. 7–12, 2021.
[21] K. Valsamidis, A. Printza, J. Constantidis, and S. Triaridis, “The impact of olfactory dysfunction on the psychological status and quality of life of patients with nasal obstruction and septal deviation,” International Archives of Otorhinolaryngology, vol. 24, pp. 237–246, 2020.
[22] B. Veyseller, B. Ozucer, A. B. Karaaltin et al., “Connecticut (CCCRC) olfactory test: normative values in 426 healthy volunteers,” Indian Journal of Otolaryngology and Head & Neck Surgery, vol. 66, no. 1, pp. 31–34, 2014.
[23] G. D. Slade, “Derivation and validation of a short-form oral health impact profile,” Community Dentistry and Oral Epidemiology, vol. 25, no. 4, pp. 284–290, 1997.
[24] Y. J. Kang, J. H. Cho, M. H. Lee, Y. J. Kim, and C.-S. Park, “The diagnostic value of detecting sudden smell loss among asymptomatic COVID-19 patients in early stage: the possible early sign of COVID-19,” Auris Nasus Larynx, vol. 47, no. 4, pp. 565–573, 2020.
[25] Y. Meng, Y. Deng, Z. Dai, and Z. Meng, “COVID-19 and anosmia: a review based on up-to-date knowledge,” American Journal of Otolaryngology, vol. 41, no. 5, Article ID 102581, 2020.
[26] N. Cirillo, “Taste alteration in COVID-19: significant geographical differences exist in the prevalence of the symptom,” Journal of Infection and Public Health, vol. 14, no. 8, 2021.
[27] P. Forster, L. Forster, C. Renfrew, and M. Forster, “Phylogenetic network analysis of SARS-CoV-2 genomes,” Proceedings of the National Academy of Sciences, vol. 117, no. 17, pp. 9241–9243, 2020.
[28] J. G. Ray, M. J. Schull, M. J. Vermeulen, and A. L. Park, “Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness,” Annals of Internal Medicine, vol. 174, no. 3, pp. 308–315, 2021.
[29] S. Boesveldt, E. M. Postma, D. Boak et al., “Anosmia-a clinical review,” Chemical Senses, vol. 42, no. 7, pp. 513–523, 2017.
[30] D. V. Santos, E. R. Reiter, L. J. DiNardo, and R. M. Costanzo, “Hazardous events associated with impaired olfactory function,” Archives of Otolaryngology—Head and Neck Surgery, vol. 130, no. 3, pp. 317–319, 2004.
[31] V. T. Kandakure, H. R. Valvi, P. Khokle, M. S. More, and R. Chouhan, “Prevalence and recovery from newly onset anosmia and ageusia in covid 19 patients at our tertiary care centre,” Indian Journal of Otolaryngology and Head & Neck Surgery: Official Publication of the Association of Otolaryngologists of India, vol. 73, pp. 1–8, 2021.
[32] J. R. Lechien, C. M. Chiesa-Estomba, D. R. De Siati et al., “Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study,” European Archives of Oto-Rhino-Laryngology, vol. 277, no. 8, pp. 2251–2261, 2020.
[33] Y. Zhu, M. Cao, P. Zheng, and W. Shen, “Residual olfactory dysfunction in Coronavirus disease 2019 patients after long term recovery,” Journal of Clinical Neuroscience, vol. 93, 2021.
[34] H. Klein, K. Asseo, N. Karni et al., “Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients,” Clinical Microbiology and Infections, vol. 27, no. 5, 2021.
[35] V. Chopra, S. A. Flanders, M. O’Malley, A. N. Malani, and H. C. Prescott, “Sixty-day outcomes among patients hospitalized with COVID-19,” Annals of Internal Medicine, vol. 174, no. 4, pp. 576–578, 2021.
[36] T. Sonneweer, S. Sahanic, A. Pizzini et al., “Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial,” European Respiratory Journal, vol. 57, no. 4, 2021.
[37] K. Stavem, W. Ghanima, M. K. Olsen, H. M. Gilboe, and G. Einvik, “Persistent symptoms 1.5–6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study,” Thorax, vol. 76, no. 4, pp. 405–407, 2021.
[38] M. S. Petersen, M. F. Kristiansen, K. D. Hanussson et al., “Long COVID in the Faroe Islands—a longitudinal study among non-hospitalized patients,” Clinical Infectious Diseases, vol. 73, no. 11, 2020.
[39] R. C. Gerkin, K. Ohla, M. G. Veldhuizen et al., “Recent smell loss is the best predictor of COVID-19 among individuals with recent respiratory symptoms,” Chemical Senses, vol. 46, 2021.
[40] L. Iannuzzi, A. E. Salzo, G. Angarano et al., “Gaining back what is lost: recovering the sense of smell in mild to moderate patients after COVID-19,” Chemical Senses, vol. 45, no. 9, pp. 875–881, 2020.
[41] R. Mahmud, M. A. Rassel, F. B. Monayem et al., “Association of ABO blood groups with presentation and outcomes of confirmed SARS CoV-2 infection: a prospective study in the largest COVID-19 dedicated hospital in Bangladesh,” PLoS One, vol. 16, no. 4, Article ID e0249252, 2021.
[42] M. Badedi, H. Darraj, A. Q. Alnami et al., “Epidemiological and clinical characteristics of deceased COVID-19 patients,” International Journal of General Medicine, vol. 14, pp. 3809–3819, 2021.
[43] Y. Okada, K. Yoshimura, S. Toya, and M. Tsuchimochi, “Pathogenesis of taste impairment and salivary dysfunction in COVID-19 patients,” American Journal of Rhinology and Allergy, vol. 57, 2021.
[44] S. Cianetti, S. Pagano, M. Nardone, and G. Lombardo, “Model for taking care of patients with early childhood caries during the SARS-cov-2 pandemic,” International Journal of Environmental Research and Public Health, vol. 17, no. 11, p. 3751, 2020.